Skip to main content

Acute Spinal Cord Injury

2
Pipeline Programs
8
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 7 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Kringle Pharma
Kringle PharmaJapan - Ibaraki
1 program
1
KP-100ITPhase 31 trial
Active Trials
NCT04475224Unknown25Est. Jun 2023
Sandoz
SandozAustria - Kundl
1 program
1
ATI355Phase 11 trial
Active Trials
NCT00406016Completed52Est. Sep 2011
Spine BioPharma
Spine BioPharmaNY - New York
1 program
Hypotension avoidanceN/A1 trial
Active Trials
NCT02232165Terminated17Est. Sep 2019
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
elezanumabN/AMonoclonal Antibody1 trial
Active Trials
NCT04278235Available
Novartis
NovartisBASEL, Switzerland
1 program
ATI355PHASE_1
United Therapeutics
United TherapeuticsMD - Silver Spring
1 program
AC105PHASE_21 trial
Active Trials
NCT01750684Terminated15Est. May 2015
Pharmazz
PharmazzIndia - Greater Noida
1 program
Normal Saline along with standard treatmentPHASE_21 trial
Active Trials
NCT04054414Recruiting40Est. Jul 2026
Daiichi Sankyo
Daiichi SankyoChina - Shanghai
1 program
SUN13837 injectionPHASE_21 trial
Active Trials
NCT01502631Completed65Est. Sep 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Kringle PharmaKP-100IT
PharmazzNormal Saline along with standard treatment
United TherapeuticsAC105
Daiichi SankyoSUN13837 injection
SandozATI355
Spine BioPharmaHypotension avoidance

Clinical Trials (7)

Total enrollment: 214 patients across 7 trials

NCT04475224Kringle PharmaKP-100IT

Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury

Start: Jul 2020Est. completion: Jun 202325 patients
Phase 3Unknown
NCT04054414PharmazzNormal Saline along with standard treatment

PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury

Start: Jan 2019Est. completion: Jul 202640 patients
Phase 2Recruiting
NCT01750684United TherapeuticsAC105

AC105 in Patients With Acute Traumatic Spinal Cord Injury

Start: Jul 2013Est. completion: May 201515 patients
Phase 2Terminated
NCT01502631Daiichi SankyoSUN13837 injection

Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)

Start: Aug 2012Est. completion: Sep 201465 patients
Phase 2Completed
NCT00406016SandozATI355

Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI

Start: May 2006Est. completion: Sep 201152 patients
Phase 1Completed
NCT04278235AbbVieelezanumab

Expanded Access to Elezanumab

N/AAvailable
NCT02232165Spine BioPharmaHypotension avoidance

Mean Arterial Blood Pressure Treatment for Acute Spinal Cord Injury

Start: Feb 2013Est. completion: Sep 201917 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 214 patients
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.